Musculoskeletal

• Joint pain and stiffness (arthralgia); early morning swelling.
• Muscle weakness (myopathy) in severe cases.
• Limited range of motion due to skin tightening.

Respiratory

• Shortness of breath, especially on exertion.
• Dry cough.
• Interstitial lung disease (fibrosis) – a leading cause of mortality.
• Pulmonary arterial hypertension (PAH) – increased pressure in the lung arteries.

Cardiovascular

• Heart rhythm abnormalities.
• Pericardial effusion (fluid around the heart).
• Myocardial fibrosis leading to heart failure.

Gastrointestinal

• Difficulty swallowing (dysphagia) due to esophageal fibrosis.
• Reflux and heartburn.
• Abdominal bloating, constipation, or diarrhea.
• Malabsorption when the small intestine is affected.

Renal

• Rapidly progressive renal crisis (scleroderma renal crisis) – sudden rise in blood pressure and kidney failure; more common in early disease.

General

• Fatigue.
• Weight loss.
• Fever (rare, often signals inflammation or infection).

Causes and Risk Factors

The exact cause of scleroderma is unknown, but research points to a combination of genetic, environmental, and immune‑mediated factors.

Genetic predisposition

• Family clustering is modest; relatives of patients have a 2–4‑fold higher risk.
• Specific HLA genes (e.g., HLA‑DRB1*11) and non‑HLA loci (e.g., STAT4, IRF5) increase susceptibility.¹

Environmental triggers

• Silica dust exposure (miners, construction workers) – strongest occupational link.²
• Solvents such as trichloroethylene.
• Viral infections (e.g., cytomegalovirus, Epstein–Barr) are hypothesized but not definitively proven.

Autoimmune dysregulation

• Abnormal activation of fibroblasts leads to excessive collagen production.
• Autoantibodies (e.g., anti‑centromere, anti‑topoisomerase I “Scl‑70”, anti‑RNA polymerase III) are present in >90 % of patients and help define disease subsets.³

Risk factors

• Female sex (especially ages 30‑50).
• History of Raynaud’s phenomenon.
• Occupational exposure to silica or organic solvents.
• Having another autoimmune disease (e.g., lupus, rheumatoid arthritis).

Diagnosis

Because scleroderma mimics many other conditions, a systematic approach is required.

Clinical evaluation

• Detailed history (onset, Raynaud’s, skin changes, organ symptoms).
• Physical exam focusing on skin thickness (modified Rodnan skin score), telangiectasias, joint range of motion, and lung/heart sounds.

Laboratory tests

• Autoantibody panel: anti‑centromere, anti‑Scl‑70, anti‑RNA polymerase III, ANA (antinuclear antibody).
• Inflammatory markers (ESR, CRP) – non‑specific but help assess activity.
• Renal function (creatinine, BUN), liver enzymes, complete blood count.

Imaging & functional tests

• High‑resolution CT (HRCT) of the chest: Detects interstitial lung disease early.
• Echocardiogram: Screens for pulmonary hypertension and cardiac involvement.
• Right‑heart catheterization: Gold standard for confirming PAH.
• Esophageal manometry & barium swallow: Assess gastrointestinal motility.
• Pulmonary function tests (PFTs): Measure forced vital capacity (FVC) and diffusing capacity (DLCO); serial testing tracks disease progression.
• Kidney ultrasound & urinalysis: Monitor for renal crisis.

Skin biopsy

Rarely needed, but can confirm excessive collagen deposition when diagnosis is uncertain.

Classification

Based on extent of skin involvement:

• Limited cutaneous systemic sclerosis (lcSSc): Skin thickening confined to face, forearms, and fingers; higher risk of PAH.
• Diffuse cutaneous systemic sclerosis (dcSSc): Extends to trunk and proximal limbs; higher risk of early internal organ involvement.

Treatment Options

Scleroderma has no cure, but treatment aims to control the immune response, limit fibrosis, and manage organ‑specific complications.

Immunomodulatory Medications

• Mycophenolate mofetil (MMF): First‑line for interstitial lung disease; improves FVC and DLCO.⁴
• Cyclophosphamide: Often used for severe lung disease or skin involvement; limited to short courses due to toxicity.
• Methotrexate: Helpful for skin and joint disease.
• Rituximab (anti‑CD20): Shows benefit in refractory lung disease and skin fibrosis (off‑label, based on emerging trials).
• Tyrosine‑kinase inhibitors (e.g., nintedanib): FDA‑approved for scleroderma‑associated interstitial lung disease; slows decline in lung function.⁵

Vasodilator Therapies (Raynaud’s & PAH)

• Calcium channel blockers (nifedipine, amlodipine) – first line for Raynaud’s.
• Endothelin receptor antagonists (bosentan, ambrisentan) – for PAH.
• Phosphodiesterase‑5 inhibitors (sildenafil, tadalafil) – improve PAH and digital ulcers.
• Prostaglandin analogs (iloprost, epoprostenol) – for severe PAH or refractory digital ulcers.

Renal Crisis Management

• Prompt ACE‑inhibitor therapy (e.g., captopril) – reduces mortality dramatically.
• Aggressive blood‑pressure control; dialysis if kidney failure develops.

Skin & Ulcer Care

• Topical steroids or tacrolimus for localized inflammation.
• Moisturizers and occlusive dressings to maintain skin pliability.
• Antibiotics for secondary infection of ulcers.
• Physical therapy to preserve joint motion.

Procedural / Surgical Options

• Laser therapy or photodynamic therapy for telangiectasias.
• Digital sympathectomy (surgical nerve interruption) in severe Raynaud’s resistant to medication.
• Lung transplantation for end‑stage pulmonary fibrosis (rare, highly selective).

Lifestyle & Supportive Measures

• Smoking cessation – critical for lung health.
• Regular aerobic exercise (guided by a physiotherapist) to maintain cardiorespiratory fitness.
• Heat protection: warm gloves, layered clothing, heated car seats to avoid Raynaud’s attacks.
• Balanced diet rich in vitamin D and calcium; monitor for malabsorption.
• Psychological support – counseling or support groups reduce anxiety and depression.

Living with Scleroderma

Managing a chronic disease involves both medical care and daily adaptations.

Self‑monitoring

• Keep a symptom diary (skin tightness, Raynaud’s frequency, shortness of breath).
• Measure blood pressure at home; report sudden spikes.
• Perform regular mouth and hand inspections for ulcers.

Regular follow‑up

Schedule:

• Every 3–6 months with a rheumatologist.
• Annual pulmonary function tests and HRCT if lung disease is present.
• Echocardiogram every 1–2 years, or sooner if dyspnea worsens.

Physical therapy

Gentle stretching, range‑of‑motion exercises, and hand therapy prevent contractures. Aquatic therapy is often well‑tolerated because water warmth reduces Raynaud’s attacks.

Skin care routine

1. Apply fragrance‑free moisturizers at least twice daily.
2. Use mild, non‑scrubbing cleansers.
3. Avoid prolonged water exposure; wear gloves when washing dishes.

Occupational considerations

• Discuss ergonomic adjustments with employers (voice‑activated keyboards, padded grips).
• Consider disability benefits if disease limits ability to work.

Emotional wellbeing

Living with an unpredictable disease can be stressful. Connect with organizations such as the Scleroderma Foundation or local support groups. Cognitive‑behavioral therapy (CBT) has shown benefit for chronic‑illness coping.

Prevention

Because the exact trigger is unknown, primary prevention is limited. However, risk can be reduced by:

• Avoiding occupational silica dust and toxic solvents; use protective equipment when exposure is unavoidable.
• Smoking cessation – smoking worsens vascular complications and lung fibrosis.
• Early treatment of Raynaud’s phenomenon, which may delay progression to full‑blown scleroderma in some individuals.
• Maintaining a healthy weight and regular exercise to support cardiovascular and pulmonary reserve.

Complications

If left untreated or inadequately managed, scleroderma can lead to serious, sometimes life‑threatening problems.

• Pulmonary arterial hypertension (PAH): A leading cause of death; can develop even with mild skin disease.
• Interstitial lung disease (ILD): Progressive fibrosis leading to respiratory failure.
• Scleroderma renal crisis: Sudden hypertension and rapidly declining kidney function.
• Cardiac involvement: Arrhythmias, myocardial fibrosis, pericardial effusion.
• Gastrointestinal dysmotility: Malnutrition, severe reflux, bacterial overgrowth.
• Digital ulcers & amputations: Due to chronic ischemia.
• Malignancy: Slightly increased risk of lung, breast, and hematologic cancers, especially in anti‑RNA polymerase III positive patients.

When to Seek Emergency Care

References

1. Mayes MD, et al. “Genetic susceptibility to systemic sclerosis.” Nat Rev Rheumatol. 2022;18:279‑295.
2. Shah AA, et al. “Silica exposure and risk of systemic sclerosis: a systematic review.” Occup Environ Med. 2021;78:765‑772.
3. Hinchcliff M, et al. “Autoantibody profiles in systemic sclerosis and clinical subsets.” Ann Rheum Dis. 2020;79:159‑166.
4. Finnson K, et al. “Mycophenolate mofetil versus cyclophosphamide for scleroderma lung disease: a meta‑analysis.” Chest. 2023;163:1122‑1134.
5. Distler O, et al. “Nintedanib for systemic sclerosis‑associated interstitial lung disease.” N Engl J Med. 2022;386:2266‑2275.

For personalized advice, always consult a rheumatologist or a healthcare professional experienced in systemic autoimmune diseases.